Cargando…
KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling
Triple‐negative breast cancer (TNBC) is an aggressive breast cancer subtype, which has poor prognosis due to the lack of effective targeted drugs. KPT‐330, an inhibitor of the nuclear export protein CRM‐1, has been widely used in clinical medicine. Y219, a novel proteasome inhibitor designed by our...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068319/ https://www.ncbi.nlm.nih.gov/pubmed/36847599 http://dx.doi.org/10.1002/2211-5463.13588 |